I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Pediatria, Neonatologia, Medicina dell’Adolescenza
e Neuropsichiatria Infantile
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532
Minerva Pediatrica 2016 Sep 08
Can clinical characteristics be criteria to perform chromosomal microarray-analysis in children and adolescents with autism spectrum disorders?
Melissa SYS 1, 2, Ann VAN DEN BOGAERT 2, Bram ROOSENS 3, Annik LAMPO 1, Anna JANSEN 4, Sara WOUTERS 1, Kathelijn KEYMOLEN 2 ✉
1 Department of Child Psychiatry, UZ Brussel, Brussels, Belgium; 2 Centre for Medical Genetics, Reproduction and Genetics, Reproduction Genetics and Regenerative Medicine, Vrije Universiteit Brussel (VUB), UZ Brussel, Brussels, Belgium; 3 Department of Internal Medicine, UZ Brussel, Brussels, Belgium; 4 Department of Child Neurology, UZ Brussel, Brussels, Belgium
BACKGROUND: Chromosomal microarray analysis (CMA) has become increasingly important in the assessment of patients with autism spectrum disorders (ASD), but is sometimes restricted to patients with specific additional characteristics or comorbidities. We aim to evaluate whether certain clinical characteristics could be criteria to perform CMA and also to investigate the diagnostic value of CMA compared to other genetic analyses in our patient population.
METHODS: The files of 311 children diagnosed with ASD were retrospectively analysed. The retrieved clinical characteristics included: intellectual disability, major congenital anomalies, epilepsy, prematurity, familial history of ASD, EEG- and MRI brain-findings. Results of the genetic analyses, including CMA, were collected and statistical analysis was performed.
RESULTS: CMA was performed in 79 patients and was found to be normal in 55 (group 1) and abnormal in 23 children (group 2). We found no statistically significant difference between groups in the presence of the clinical characteristics. The diagnostic yield of CMA (8.9%) was higher than in conventional karyotyping (1.6%) and other genetic analyses (3.8%).
CONCLUSIONS: In our study, there was no significant difference in the presence of clinical characteristics in patients diagnosed with ASD who had abnormal CMA results compared to patients with normal CMA results. Therefore, the presence of these characteristics should not be used as criteria to perform CMA. Secondly, the diagnostic yield of CMA is higher than that of other genetic analyses. Our study supports the general recommendation that CMA should be offered as a first-tier test in the assessment of patients with ASD.